{
    "Trade/Device Name(s)": [
        "MAGLUMI 2000 HCG",
        "MAGLUMI 2000 \u03b2-HCG"
    ],
    "Submitter Information": "Shenzhen New Industries Biomedical Engineering Co., Ltd.",
    "510(k) Number": "K192547",
    "Predicate Device Reference 510(k) Number(s)": [
        "K130020"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DHA"
    ],
    "Summary Letter Date": "January 17, 2020",
    "Summary Letter Received Date": "December 10, 2019",
    "Submission Date": "December 6, 2019",
    "Regulation Number(s)": [
        "21 CFR 862.1155"
    ],
    "Regulation Name(s)": [
        "Human Chorionic Gonadotropin (HCG) Test System"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "endocrine"
    ],
    "Analyte(s)": [
        "Total beta human chorionic gonadotropin (\u03b2-HCG)"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "MAGLUMI 2000"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescence immunoassay"
    ],
    "Methodologies": [
        "Sandwich immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Kit",
        "Reagent",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for MAGLUMI 2000 HCG/\u03b2-HCG chemiluminescence immunoassay for quantitative determination of total \u03b2-hCG in human serum",
    "Indications for Use Summary": "In vitro chemiluminescence immunoassay for the quantitative determination of total beta human chorionic gonadotropin (\u03b2-hCG) in human serum, used as an aid in the early detection of pregnancy",
    "fda_folder": "Clinical Chemistry"
}